

Raw Material Identity Testing:

Transforming a Quality-Control Bottleneck into a Strategic Manufacturing Advantage

Executive Summary

For years, identity verification of biological raw materials has occupied a somewhat uncomfortable position in biomanufacturing. Everyone recognizes its importance, yet analytical workflows are fragmented, difficult to standardize, and often prohibitively expensive to implement. As a result, incoming raw materials frequently remain under-characterized throughout early-stage development, with manufacturers relying largely on supplier Certificates of Analysis (CoA) or analytical methods not designed for routine identity verification of complex biological mixtures.

In many organizations, comprehensive incoming raw material testing is deferred until late-stage clinical development or commercial manufacturing when regulatory expectations become more stringent and process changes become increasingly costly. While this approach minimizes early development expenses, it can also limit process understanding, increase technical risk, and delay identification of material-related sources of variability.

The challenge is becoming more significant as advanced therapies mature. Although many established biologics, such as monoclonal antibodies, are now manufactured using chemically defined media, numerous emerging platforms in cell therapy, regenerative medicine, tissue engineering, and personalized medicine continue to rely on complex biological raw materials. Cytokine and growth factor mixtures, serum-derived supplements, extracellular matrix proteins, conditioned media, enzymes, and other biologically-derived inputs often contain dozens to hundreds of functionally important components whose identity and consistency can directly influence manufacturing outcomes.

As cell culture systems become increasingly sophisticated, manufacturers face growing pressure to understand exactly what is entering their processes. Raw material variability is widely recognized as a source of manufacturing risk, and regulatory agencies increasingly emphasize supplier qualification, material characterization, traceability, and control of critical process inputs (e.g., ISO/AWI 20399-4:2025, USP<1043>, Ph.Eur. 5.2.12). Industry standards and guidance documents similarly encourage a more comprehensive understanding of raw materials throughout the product lifecycle.

Biothentix™ was designed to address this challenge. Using standardized multiplex assays, Biothentix enables rapid identity verification of complex biological raw materials in less than one work day, typically under 2 hours, while supporting harmonized testing across suppliers, manufacturers, CDMOs, and contract testing laboratories. Importantly, the platform enables suppliers to verify critical components without disclosing proprietary formulations, creating a framework for transparency and trust that preserves intellectual property.

The result is a fundamental shift in how raw material identity testing is viewed. Instead of a late-stage regulatory obligation, identity testing becomes a strategic tool that accelerates development, reduces risk, improves quality, and strengthens supply-chain collaboration.

The Hidden Risk of Complex Biological Raw Materials

Modern biomanufacturing depends on a wide range of critical raw materials. While chemically defined components have become increasingly common, many advanced manufacturing processes still rely on complex biological inputs whose composition is not currently fully understood. For regenerative medicines, even chemically defined media can contain a mixture of critical proteins whose identity, and ideally, quantity and integrity are critical process parameters.

Example components in complex cell culture media:

- Human serum albumin
- Cytokines
- Growth factors
- Enzymes
- Extracellular matrix preparations
- Fetal bovine serum
- Human platelet lysate
- Hydrolysates and protein digests

These materials often exert profound influence on cell phenotype, expansion rates, differentiation pathways, viability, potency, and manufacturing consistency.

Yet many organizations possess surprisingly limited visibility into the biological composition of these inputs.

A supplier's CoA may confirm that a material meets predefined specifications, but it rarely provides direct evidence that critical biological constituents are present in the expected relative proportions. Likewise, traditional analytical methods often examine only one or two targets at a time, making comprehensive characterization impractical.

Consequently, variability originating in raw materials may remain undetected until significant development effort has already been invested.

The cost of discovering such variability increases dramatically as programs advance from research into clinical manufacturing.



Why Identity Testing Traditionally Begins Too Late

Historically, incoming raw material identity testing has been treated primarily as a quality control activity rather than a development tool.

Several factors contribute to this mindset:

- High analytical cost
- Long turnaround times
- Specialized instrumentation requirements
- Limited flexibility in assay design
- Lack of standardized methods
- Difficulty transferring assays across organizations

As a result, developers often defer implementation until Phase 3 studies or commercial readiness initiatives.


This creates a paradox.

The stage at which organizations possess the least process knowledge is precisely the stage at which deeper raw material characterization could provide the greatest benefit.

Without visibility into incoming materials, process developers may unknowingly attribute variability to cell lines, operators, equipment, or manufacturing conditions when the true source originates in a critical raw material.

Timing Changes Everything

The earlier you test, the less it costs—and the more you gain.





Earlier implementation of identity testing can dramatically improve process understanding while corrective actions remain relatively inexpensive and have far fewer downstream ramifications.

Transforming Identity Testing into a Process Development Tool

Raw material identity testing creates value long before commercial manufacturing begins.

During process development, manufacturers seek to answer fundamental questions:

- Which media components drive performance?
- How sensitive is the process to supplier variability?
- Which materials represent critical process inputs?
- Which attributes correlate with process outcomes?
- What specifications should ultimately be controlled?

Traditional approaches often rely on trial-and-error experimentation.

By characterizing biological inputs early in development, organizations can establish stronger relationships between raw material composition and manufacturing performance.

Benefits of using a flexible, ideally multiplex, analytical tool early in process development include:

Faster Root Cause Investigations

Unexpected process performance can be correlated with material fingerprints rather than relying solely on retrospective investigations.

Improved Comparability Studies

Supplier changes, lot changes, and formulation modifications can be evaluated against objective identity measurements.

Better Process Understanding

Manufacturers gain insight into which biological inputs contribute most significantly to variability.

Earlier Risk Mitigation

Potential supply-chain vulnerabilities can be identified before clinical manufacturing begins. Identity testing therefore becomes part of a process-development strategy rather than merely a release-testing requirement.



The Biothentix Solution

Biothentix combines multiplex assay technology with standardized workflows ideal for efficient biological raw material testing.

Key platform attributes include:

- Multiplex identification and quantification of numerous biological targets simultaneously
- Less than two-hour turnaround time
- Digital, traceable analytical results
- 21 CFR Part 11-compatible software
- Standardized reagent kits manufactured under ISO 13485 quality systems
- Proven integration into quality-control workflows
- Efficient and affordable custom assay development
- Single-platform workflow replacing multiple analytical methods
- Scalable deployment across suppliers, developers, CDMOs, and testing laboratories

Unlike traditional methods that evaluate one analyte at a time, Biothentix provides a broader view of biological identity while reducing analytical burden.

The Future of Raw Material Control

Advanced therapies are becoming increasingly complex. Regulatory expectations continue to evolve. Supply chains are becoming more interconnected. Manufacturing organizations are under constant pressure to reduce risk while accelerating development timelines.

In this environment, raw material identity testing can no longer be viewed solely as a late-stage quality control activity.

Organizations that implement identity testing early gain a strategic advantage through improved process understanding, reduced manufacturing risk, more efficient technology transfer, and stronger supplier relationships.

The future of raw materials control is not simply testing more materials. It is understanding them better and earlier in the process.

Biothentix™ enables that future by transforming raw material identity testing from a compliance exercise into a foundation for process knowledge, manufacturing confidence, and supply-chain harmonization. Contact InDevR at Sales@InDevR.com.